Shenzhen New Industries launches 100M CNY share buyback amid stock decline
Shenzhen New Industries Biomedical Engineering, a major player in China's in-vitro diagnostics and analytical equipment sector, has seen its stock struggle in recent months. The company's shares dropped by 3.37% on Thursday, reaching a daily low of 48.03 CNY. This decline comes as the firm announces a new share buyback programme to stabilise its performance. The company's board approved a buyback plan for A-shares worth up to 100 million CNY in early March. The maximum repurchase price was set at 70 CNY per share. These repurchased shares will be used for employee stock ownership schemes and incentive programmes.
Shenzhenew Industries has faced a difficult year, with its stock falling over 14% since January. Over the past 12 months, its performance has lagged behind the broader market, declining between 3.15% and 14.10%. This underperformance contrasts with the company's strong financial fundamentals, including a price-to-earnings ratio of 32 and a return on equity above 18%. Despite recent stock weakness, the business has shown consistent growth. Annual revenue has increased by an average of 16% over the last five years, while operating profits have risen by around 14% each year. However, the broader Chinese equity market's struggles may continue to weigh on the stock in the near term.
The buyback programme aims to support share value and fund employee incentives. With a solid financial track record, the company remains a key name in China's diagnostics industry. Yet, its short-term stock performance will likely depend on wider market conditions.
